Meet us at Booth #31107 and discover how Veracyte’s molecular tests empower clinicians with the high-value insights needed in the race to diagnose and treat cancer.

We are excited to announce 8 abstracts/posters, which will showcase data on Decipher Prostate, Decipher Bladder, and Decipher GRID.

See the schedule below for dates and times to view these presentations.

SATURDAY, MAY 31, 2025 

1:15 PM – 2:45 PM CDT

• Abstract #4518: First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC).

Presented by: Andrea Necchi, MD

Arie Crown Theater | Live Stream

MONDAY, JUNE 2, 2025 

9:00 AM – 12:00 PM CDT

• Abstract #5089 | Poster Bd #288: Prognostic validation of six androgen production, uptake, and conversion genes (APUC-6) in the CHAARTED prostate cancer trial.

Presented by: Xiaolei Shi, MD, PhD

Hall A – Posters and Exhibits | On Demand

• Abstract #4591 | Poster Bd #391: First survival outcomes and biomarker results of SURE-01: Neoadjuvant sacituzumab govitecan (SG) monotherapy, followed by radical cystectomy (RC), in patients with muscle-invasive urothelial bladder cancer (MIBC).

Presented by: Brigida Anna Maiorano, MD

Hall A – Posters and Exhibits | On Demand

• Abstract #4594| Poster Bd #394: Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).

Presented by: Chiara Mercinelli, MD

Hall A – Posters and Exhibits | On Demand

• Abstract #4595 | Poster Bd #395: Five-year median follow-up update of PURE-01: A phase 2 study of neoadjuvant pembrolizumab followed by radical cystectomy in patients with muscle-invasive bladder cancer (MIBC).

Presented by: Valentina Tateo, MD

Hall A – Posters and Exhibits | On Demand

9:45 AM – 12:45 PM CDT

• Abstract  #5003:  Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): An ancillary study of the STAMPEDE trials.

Presented by: Emily Grist, PhD, MBBS, MRCP, BSc

Hall D1 | Live Stream

FOR PUBLICATION ONLY

• e17140: Real-world analysis of primary tumor transcriptomes in patients subsequently treated with PARP inhibitors.

First author: Ashley Ross, MD

• e17052: Loss of ANPEP expression may promote the development of aggressive prostate cancer.

First author: Ryan Putney